Sagimet Biosciences Inc. - 8-K Filing
Sagimet Biosciences updates investor presentation detailing denifanstat clinical milestones and $257.6M cash position. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $SGMT
Read the full article at SEC EDGAR
Part of the story First Breach, Inc. - 8-K Filing (3 articles)